Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis

2024-518288-37-00 Protocol R5459-1979-LN-2459 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 18 Dec 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 8 sites · Protocol R5459-1979-LN-2459

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 60
Countries 3
Sites 8

Lupus Nephritis

Key facts

Sponsor
Regeneron Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
18 Dec 2025 → ongoing
Decision date (initial)
2025-10-07
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-518288-37-00
ClinicalTrials.gov
NCT06975787

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Lupus Nephritis

VersionLevelCodeTermSystem organ class
21.1 PT 10025140 Lupus nephritis 100000004857

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Regeneron Pharmaceuticals Inc.

Sponsor organisation
Regeneron Pharmaceuticals Inc.
Address
777 Old Saw Mill River Road
City
Tarrytown
Postcode
10591-6717
Country
United States

Scientific contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Medical Affairs

Public contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Medical Affairs

Locations

3 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 6 1
Germany Ongoing, recruiting 4 2
Spain Authorised, recruitment pending 9 5
Rest of world
Taiwan, Israel, United States, Korea, Republic of, Philippines
41

Investigational sites

France

1 site · Authorised, recruitment pending
Centre Hospitalier Universitaire De Bordeaux
250001: Nephrology, Place Amelie Raba Leon, 33000, Bordeaux

Germany

2 sites · Ongoing, recruiting
Universitaetsklinikum Regensburg AöR
276001: Abteilung für Nephrologie, Franz-Josef-Strauss-Allee 11, Grass-Oberisling, Regensburg
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
276002: I.Medizinische Klinik und Poliklinik, Nephrologie, Langenbeckstrasse 1, Oberstadt, Mainz

Spain

5 sites · Authorised, recruitment pending
Hospital Universitario Regional De Malaga
724004;Reumatología, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Universitario 12 De Octubre
724005: Nefrología, Avenida De Cordoba Sn, 28041, Madrid
University Hospital Virgen Del Rocio S.L.
724002;Nefrología, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital General Universitario Gregorio Maranon
724001;Nefrología, Calle Del Doctor Esquerdo 46, 28009, Madrid
Clinica Universidad De Navarra
724003;Nefrología, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-12-18 2025-12-18

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-19 Spain Acceptable
2025-10-03
2025-10-07
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-17 Spain Acceptable 2025-10-24
3 SUBSTANTIAL MODIFICATION SM-2 2026-01-21 Spain Acceptable
2026-04-27
2026-04-28